Alaska Permanent Fund

The Alaska Permanent Fund is a constitutionally established permanent fund managed by a state-owned corporation, the Alaska Permanent Fund

Business Model:

Revenue: $9.4B

Employees: 51-200

Rankings

Detailed Alaska Permanent Fund Information

Geographic Data

Alaska Permanent Fund headquarters map

Address: 801 W 10th Street Suite 302

City: Juneau

State: AK

Zip: 99801

Country: US

Financial Info

Stage:

Raised Last:

$100M

Raised Total:

$100M

Metrics

3,152,688Website Global Rank

5,170Website Monthly Traffic

Twitter Followers

Description

The Alaska Permanent Fund is a constitutionally established permanent fund managed by a state-owned corporation, the Alaska Permanent Fund Corporation. The fund was established in Alaska in 1976 by Article 9, Section 15 of the Alaska State Constitution under Governor Jay Hammond. From February 1976 until April 1980, the Department of Revenue Treasury Division managed the state&s;s Permanent Fund assets, until, in 1980, the Alaska State Legislature created the APFC. Shortly after the oil from Alaska’s North Slope began flowing to market through the Trans-Alaska Pipeline System, the Permanent Fund was created. It was designed to be an investment where at least 25% of the oil money would be put into a dedicated fund for future generations, who would no longer have oil as a resource. This does not mean the fund is solely funded by oil revenue. The Alaska Permanent Fund sets aside a certain share of oil revenues to continue benefiting current and all future generations of Alaskans.

Contact Phone:
+19077961500

Contact Email:

Announced Date Company Transaction Money Raised
12/2021 NorthLink Aviation Venture Round -
5/2015 Denali Therapeutics Series A 217M
8/2020 Indigo Series F 360M
12/2013 Juno Therapeutics Series A 120M
4/2021 Repertoire Immune Medicines Series B 0
11/2017 Codiak Biosciences Series C 76.5M
11/2021 Generate Biomedicines Series B 0
4/2022 Tessera Therapeutics Series C 0
1/2021 Tessera Therapeutics Series B 0
8/2014 Juno Therapeutics Series B 134M
1/2016 Codiak Biosciences Series B 61M
6/2020 Sana Biotechnology Series A 700M
7/2016 Indigo Series C 100M
8/2016 Denali Therapeutics Series B 130M
9/2018 Indigo Series E 250M
9/2017 Indigo Series D 203M
4/2022 Tessera Therapeutics Series C 0
12/2021 NorthLink Aviation Venture Round -
11/2021 Generate Biomedicines Series B 0
4/2021 Repertoire Immune Medicines Series B 0
1/2021 Tessera Therapeutics Series B 0
8/2020 Indigo Series F 0
6/2020 Sana Biotechnology Series A 0
9/2018 Indigo Series E 0
11/2017 Codiak Biosciences Series C 0
9/2017 Indigo Series D 0

Startup Industries

Startup Locations

Portfolio Current Status

Portfolio Employee Count

Name Price
Name Size Announced Date

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research